Study of BMN-270 at a dose of 6e13vg/kg in patients with severe haemophilia A
Phase of Trial: Phase III
Latest Information Update: 04 Aug 2017
At a glance
- Drugs BMN 270 (Primary)
- Indications Haemophilia A
- Focus Registrational; Therapeutic Use
- 04 Aug 2017 New trial record
- 02 Aug 2017 Results published in the BioMarin Pharmaceutical media release.
- 02 Aug 2017 According to a BioMarin Pharmaceutical media release, the study will include fewer than 100 patients.